New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 5, 2014
08:07 EDTNVOZosano Pharma enters into license agreement with Novo Nordisk
Zosano Pharma announced that it has entered into an agreement with Novo Nordisk to develop a new transdermal presentation of semaglutide, an investigational proprietary human GLP-1 analogue, to be administered once weekly using Zosano's microneedle patch system for the treatment of type 2 diabetes. Initially, Zosano and Novo Nordisk will engage in collaborative efforts to carry out preclinical experiments to verify delivery of semaglutide using Zosano's microneedle patch system. Under the terms of the agreement, Zosano will grant Novo Nordisk a worldwide, exclusive license to develop and commercialize Novo Nordisk's proprietary GLP-1 analogues using Zosano's microneedle patch system. Potential payments to Zosano under the agreement include an upfront payment and additional payments upon achieving certain preclinical, clinical, regulatory and sales milestones. Such payments could total more than $60M for the first product and $55M for each additional product.
News For NVO From The Last 14 Days
Check below for free stories on NVO the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
July 14, 2014
07:20 EDTNVOControlled Released Society to hold annual meeting
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use